Date Title
7/15/2008 Amgen Scientists Recognized for “Most-Cited” Paper on Osteoclast Differentiation
  Amgen researchers are being recognized for their impact on the field of bone biology for a 2003 Nature article, which is “the highest cited paper” in its research area, according to Thomson Reuters’ ScienceWatch website. more >
11/3/2006 Amgen Honors 32 Teachers with 2008 Science Teaching Award
 
Throughout April and May, Amgen honored 32 science teachers in the United States, Puerto Rico and Canada as the 2008 recipients of the 17th annual Amgen Award for Science Teaching Excellence (AASTE). All of the teachers were selected for their outstanding contributions to science education and their ability to instill a passion for discovery in young learners. more >
6/16/2008 Amgen Statement on Briefing Materials Prepared for June 18, 2008 DODAC Meeting
  Briefing documents for the June 18 Dermatologic and Ophthalmic Drugs Advisory (DODAC) meeting regarding the supplemental biologics license application (sBLA) for Enbrel® for the treatment of moderate to severe plaque psoriasis in the pediatric population are now available at www.fda.gov. more >
6/3/2008 Unmasking the Mystery Signal that Controls Bone Growth
 
Amgen’s sclerostin research ties in well with the latest thinking about bone biology at the cellular level. It has been known for a long time that skeletal adaptation is greatly influenced by mechanical strain. How does the skeleton “feel” mechanical strain? How does it turn this information into the act of making more or less bone? This has been a central question in bone biology for many years. more >
5/16/2008 Millions of Reasons to Move in May: Amgen Proudly Celebrates Arthritis Awareness Month
 
May is Arthritis Awareness Month, and Amgen, a long-time supporter of the Arthritis Foundation, is helping promote awareness, education and prevention of arthritis, a disease that affects 46 million Americans. more >
4/29/2008 Leading Thinkers and Teach For America Corps Members Attend Annual Summit
  For approximately 100 Amgen Fellows, attending the second annual Amgen-Teach For America Mathematics and Science Summit, April 11-13, was more than a chance to visit Stanford University in California during a warm spring weekend. It was an opportunity to discuss with other current Teach For America corps members and alumni, policy makers and industry leaders the ways of strengthening math and science education in the under-resourced urban and rural areas where they teach. more >
4/29/2008 Amgen’s Joe Miletich Is a Guest Teacher at a Los Angeles School During Teach For America Week
  On April 14, Dr. Joe Miletich, Amgen’s senior vice president of Research and Development, participated in the annual Teach For America Week as a guest teacher in Amgen Fellow Eloy Romero’s eighth grade science class at Foshay Learning Center in Los Angeles. During his visit, Miletich shared with students his personal education and science career path, talked about the life of a scientist, and answered student questions. more >
2/25/2008 Amgen Foundation Expands Giving to Europe
 
The Amgen Foundation is proud to expand its philanthropic giving to organizations chartered in Europe through a partnership with United Way International (UWI). Charitable giving is a tangible demonstration of Amgen’s core values and reflects responsible use of limited funds which create value through programs that have a real impact. more >
2/17/2008 2008 Amgen Tour of California Under Way Feb. 17-24
  The Amgen Tour of California, a world-class professional cycling race, kicks off in Palo Alto on Feb. 17 and concludes in Pasadena on Feb. 24. Amgen’s title sponsorship of the race and its complementary Breakaway from Cancer™ initiative allows the company to raise awareness of vital support and educational resources available to people affected by cancer. more >
1/10/2008 Amgen Statement on Alzheimer's Case Study
  A study titled “Rapid Cognitive Improvement in Alzheimer’s Disease Following Perispinal Etanercept Administration” was published this week in the Journal of Neuroinflammation.  It is important to note that the study published was a case study involving a single patient. more >
1/2/2008 Amgen Researchers Deliver Milestones in Women’s Genome Health Study Collaboration
 
The Amgen research team in charge of conducting a genome-wide screen of the 28,000 participants in the Women’s Genome Health Study has submitted analysis of 3 billion genotypes, representing about 8,200 individuals, to the company’s collaborators at the renowned Brigham & Women’s Hospital in Boston, Mass. more >
9/7/2007 Amgen Presents at FDA CRDAC Meeting on September 11, 2007
  On Tuesday, September 11, 2007, the U.S. Food and Drug Administration (FDA) held a joint meeting of the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) and the Drug Safety and Risk Management Committee. At this meeting, Amgen presented data on the safety and efficacy of erythropoiesis-stimulating agents (ESAs) in chronic renal failure. more >
8/14/2007 Amgen Research Experiment Launches with Latest NASA Shuttle: First Space-based Study of Muscle Loss Therapy
 
When NASA’s space shuttle Endeavour launched on Aug. 8, its payload included the first space-based experiment on a muscle-loss therapeutic, a myostatin inhibitor, which is being developed by Amgen and investigated for its effectiveness in muscle-wasting diseases. more >
6/13/2007 Amgen Foundation and NSTA Unveil Professional Development Program for New Science Teachers
 
The Amgen Foundation and the National Science Teachers Association (NSTA), the largest professional organization in the world promoting excellence and innovation in science teaching, have announced a new program to support middle and secondary school science educators in their first years of teaching.
more >
6/7/2007 Amgen CEO Responds to New York Times Article on ESAs
 
Amgen CEO Kevin Sharer recently sent a letter to the editors of The New York Times in response to that publication's May 9 front page story and May 14 editorial on the use of anti-anemia drugs. more >
6/2/2007 Amgen Submits Comments in Response to CMS’ Proposed National Coverage Decision
 
Amgen has posted its comments in response to the Centers for Medicare and Medicaid Services’ (CMS) Proposed Decision Memorandum (PDM) for Erythropoiesis Stimulating Agents (ESAs) for Non-Renal Disease Indications (CAG-00383N) released on May 14, 2007. more >
5/4/2007 Amgen Foundation Releases 2006 Corporate Contributions Report
 
The Amgen Foundation, the company’s philanthropic arm, continues to strengthen Amgen engagement in the community by supporting programs that advance science education, improve patient care and support vital community resources. more >
3/9/2007 Update to U.S. Prescribing Information for Aranesp® and EPOGEN®
 
Amgen is committed to the highest standards of patient safety. The well-being of patients is Amgen’s highest priority. more >
3/9/2007 Amgen’s Statement on the Safety of Aranesp® (darbepoetin alfa) and EPOGEN® (Epoetin alfa)
 
Patient safety and the appropriate use of all of our products are top priorities for Amgen. Reports from several experimental studies evaluating the class of drugs known as erythropoiesis-stimulating agents (ESAs), including Aranesp® (darbepoetin alfa), EPOGEN® (Epoetin alfa), Procrit® (Epoetin alfa), NeoRecormon® (Epoetin beta) and Eprex® (Epoetin alfa), have raised safety concerns regarding the off-label use of these products to correct anemia or raise hemoglobin concentrations. more >
2/5/2007 Amgen Receives Award for “Best Biotechnology Pipeline”
 
Amgen was awarded “Best Biotechnology Pipeline” by the editors of R&D Directions and Med Ad News and once again made the publications’ list of Top 10 biotechnology and pharmaceutical pipelines. more >
1/8/2007 Amgen Named One of FORTUNE’s “100 Best Companies to Work For”
 
Once again, Amgen has been named by FORTUNE magazine as one of the “100 Best Companies to Work For.” This year, Amgen ranked number 40, and among the five biotechnology/pharmaceutical industry companies appearing on this prestigious list, Amgen ranked second. Amgen has been selected as one of the “100 Best Companies to Work For” a total of eight times. more >
12/8/2006 Amgen Promotes Breakaway from Cancer™ Initiative
 
The quest to relieve the suffering of cancer patients has many partners. That’s why Amgen has created the Breakaway from Cancer™ initiative, which strives to support nonprofit organizations that provide valuable services and programs to support cancer survivorship. more >
12/4/2006 Amgen Policy on the Support of U.S. Clinical Practice and Treatment Guidelines
 
Amgen believes that clinical practice and treatment guidelines assist in setting appropriate standards for therapeutic management by healthcare professionals. Consistent with Amgen’s mission to serve patients, we will under some circumstances choose to provide financial support to qualified independent bodies that develop such guidelines. more >
11/20/2006 Amgen Responds to CHOIR and CREATE Clinical Trial Data
 
Amgen is committed to the highest standards of patient safety. The well-being of patients is Amgen’s highest priority. Recently, the New England Journal of Medicine published the results of experimental studies called CHOIR (conducted by Johnson & Johnson) and CREATE (conducted by Roche) that have raised questions about the wisdom of aggressive treatment of anemia in patients with chronic kidney disease (CKD) that are not on dialysis.  While we expect that discussion of these results will continue within the medical community for some time, it is important to place these results in the context of what is already known about anemia treatment. more >
11/3/2006 Amgen Recognizes Science Teachers
 
Long after the dismissal bell rings, many teachers can be found correcting papers, tutoring students who need extra help, and developing creative lesson plans. Earlier this year, an “A+” was given to 19 science teachers, all of whom were recipients of the annual Amgen Award for Science Teaching Excellence (AASTE). more >
10/25/2006 Amgen to Collaborate with Brigham and Women’s Hospital to Study Genetic Causes of Disease in Women
 
Amgen has entered into a collaboration with the renowned Brigham and Women’s Hospital in Boston, Mass., that may identify the genetic variations in American women underlying a range of serious illnesses, including heart disease, stroke, diabetes, breast cancer and osteoporosis. more >
7/14/2006 Enbrel® Honored as “Brand of the Year” by Med Ad News
 
Enbrel® (etanercept) was acclaimed “Brand of the Year” by Med Ad News, a leading healthcare industry magazine, marking the first time that a biologic therapy has received the honor. The distinction appeared in the June issue of Med Ad News. more >
7/6/2006 Amgen Foundation Releases 2005 Annual Report
 
Last year, the Amgen Foundation, the company’s philanthropic arm, provided $17 million in grants to approximately 160 nonprofit groups working to advance science education, improve patient care and support community resources. The 2005 Amgen Foundation Charitable Contributions Report, now available in print and online, tells the stories of several of these organizations and how they are making a positive difference in people’s lives. more >
3/28/2006 Amgen Ranked No. 9 on BusinessWeek Top 50 “Best Performers” List
 
Amgen is ranked No. 9 on BusinessWeek’s 2006 list of Top 50 best-performing companies. Amgen is the leading biotechnology company in the ratings and one of only two biotechnology companies named to the list. more >
1/10/2006 Amgen Named One of FORTUNE's "100 Best Companies to Work For"
 
Amgen has once again been named by FORTUNE magazine as one of the "100 Best Companies to Work For." This year, Amgen ranked number 39, and of the five biotechnology/pharmaceutical industry companies appearing on this elite list, Amgen ranked third. more >
10/3/2005 Amgen Takes Top Honors in Three Prestigious Publications
 
In two respected publications-Pharmaceutical Executive and Science-Amgen received high scores, capturing the number 1 and 2 spots over Johnson & Johnson, Eli Lilly, Merck, Pfizer and numerous other pharmaceutical and biotech companies. more >
9/16/2005 FDA Expands Neulasta® Label
 
New Label Extends First-Cycle Protection From Infection To Cancer Patients Receiving Moderately Myelosuppressive Chemotherapy

Amgen’s efforts to help cancer patients received an important boost on September 15, when the U.S. Food and Drug Administration (FDA) approved an update to the Neulasta® (pegfilgrastim) prescribing information to include data from a landmark Phase 3 study demonstrating the white blood cell booster helps protect patients with most types of cancer undergoing moderately myelosuppressive chemotherapy from infection, as manifested by febrile neutropenia (low white blood cell count with fever), one of the most serious side effects of chemotherapy. more >
9/2/2005 Amgen Donates $2.5 Million to Hurricane Katrina Relief Efforts
 
Amgen (Nasdaq:AMGN), the world's largest biotechnology company, today announced that it is providing an initial cash contribution of $2.5 million and establishing a company-wide Hurricane Katrina Relief Program in support of humanitarian aid, with a special focus on access to health care. A portion of Amgen's contribution will go to the American Red Cross for general aid to the region and the balance will support organizations that can assist in providing access and continuity of care for patients in the Gulf Coast area, especially dialysis and oncology patients. more >
8/12/2005 Amgen Foundation Releases 2004 Annual Report
 
The Amgen Foundation made grants last year totaling more than $16 million to more than 130 not-for-profit local, regional and non-profit groups. Several of these grant recipients are highlighted in the 2004 Amgen Foundation Charitable Contributions Report. more >
6/3/2005 Enbrel® Expands Indication
 
Enbrel® (etanercept), the Amgen therapeutic that is indicated for five distinct diseases - moderate -to-severe rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, moderate-to-severe psoriasis and psoriatic arthritis - recently received its 10th approval from the Food and Drug Administration (FDA) to improve physical function in psoriatic arthritis patients with active arthritis. more >
4/8/2005 Amgen Marks 25th Anniversary
 
In 2005, Amgen celebrates its 25 th anniversary. Twenty-five years ago, we believed that biotechnology had the power to restore health, even save lives. Today, we’ve come further than we ever would have dreamed possible. more >